Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PS-DNA-MB is a phosphorothioate-modified DNA molecular beacon designed for the early detection of gastrointestinal malignancies by targeting specific K-ras oncogene mutations. Molecular beacons are hairpin-shaped oligonucleotide probes that become fluorescent upon hybridization with a complementary target sequence. The phosphorothioate (PS) modification involves replacing a non-bridging oxygen atom in the phosphate backbone with a sulfur atom, which enhances resistance to nuclease degradation. In research settings, PS-DNA-MB has been evaluated for its ability to detect the codon 12 K-ras mutation (GGT→GAT) in various cell lines, although it has shown slower hybridization kinetics and lower specificity in complex RNA environments compared to peptide nucleic acid (PNA) based probes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phosphothioated DNA molecular beacon.